Drug Trials Snapshots: JESDUVROQ

JESDUVROQ is a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor that treats anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.

Source: FDA Center for Drug Evaluation and Research - What's New - February 22, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news